DE&I: Understanding That We Don’t Understand at Molecular Level
BioSpace · BioSpace
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This is the second episode of Denatured's discussion on diversity, equity and inclusion (DE&I).
Data is the essential piece for both science and technology. The lack of DE&I data is becoming even more imperative as we move towards personalized medicines. Without understanding why there are differences in outcomes, the industry will continue to see worsening outcomes. However, DE&I is still not at the forefront of the mind during clinical trial designs, which influences not only the training but the application of AI models. Additionally, what this means not only for life sciences but also for healthcare providers as more of the healthcare industry adopts AI to assist with patient care.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Dr. Ali Pashazadeh, CEO,Treehill Partners
Dr. Charlotte Jones-Burton, Board Member, bluebird bio; Founder & President, Women of Color in Pharma
Chia Chia Sun, Chief Commercial Officer, Fab Biopharma; CEO, Damiva
Phyllis Greenberger, Senior Vice President, Policy & Regulatory, Healthy Women
Dr. Todd Rudo, Chief Medical Officer, Clario